(19)

(11)

EP 4 526 333 A2

(12)

(88) Date of publication A3: 08.02.2024 (43) Date of publication: 26.03.2025 Bulletin 2025/13 (21) Application number: 23808207.7 (22) Date of filing: 16.05.2023

(51) International Patent Classification (IPC):  C07K 14/705(2006.01) C12N 15/62(2006.01) C12N 5/0783(2010.01) C12N 15/85(2006.01) C12N 15/11(2006.01) C12N 5/071(2010.01) C12N 9/22(2006.01) (52) Cooperative Patent Classification (CPC): C07K 14/705; C12N 9/22; C12N 2310/20; C12N 15/1138; C07K 14/7051; C07K 2319/03; A61K 40/11; A61K 40/31 (86) International application number: PCT/US2023/022439 (87) International publication number: WO 2023/225035 (23.11.2023 Gazette 2023/47)

(84) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR Designated Extension States: BA Designated Validation States: KH MA MD TN (30) Priority: 16.05.2022 US 202263342472 P (71) Applicant: Celyntra Therapeutics SA 1435 Mont-Saint-Guibert (BE)	(72) Inventors: WARNECKE, Tanya Boulder, Colorado 80301 (US) BAUMGARTNER, Roland Boulder, Colorado 80301 (US) SCHIEL, John Boulder, Colorado 80301 (US) TIMMINS, Nicholas Eion Boulder, Colorado 80301 (US) (74) Representative: Nederlandsch Octrooibureau  P.O. Box 29720 2502 LS The Hague 2502 LS The Hague (NL)